HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.
JP Morgan Maintains Overweight on Plug Power, Lowers Price Target to $24
JP Morgan analyst Bill Peterson maintains Plug Power (NASDAQ:PLUG) with a Overweight and lowers the price target from $28 to $24.